NASDAQ · ANEB
Healthcare · Biotechnology
$0.42
Up+$0.10 (+31.25%)
Updated Aug 17, 2026, 9:27 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ANEB does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ANEB.
ANEB research
Company profile and research snapshot.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 23, 2025 | Maxim Group | Hold | — |
| May 15, 2025 | Maxim Group | Buy | — |
| Nov 19, 2024 | Benchmark | Speculative Buy | — |
| Oct 1, 2024 | Benchmark | Speculative Buy | — |
| Oct 3, 2023 | Benchmark | Speculative Buy | — |
No generated briefing is available yet.
Benzinga · Feb 12, 2026
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 44.44 percent increase over losses of $(0.09) per
Benzinga · Feb 12, 2026
SEC.
Benzinga · Feb 6, 2026
Benzinga · Feb 6, 2026
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANEB.
